scholarly journals Hepatic Disfunction in Renal Cell Carcinoma: A Stauffer Syndrome Variant

2021 ◽  
Vol 1 (1) ◽  
pp. 69-73
Author(s):  
Bogdan Silviu Ungureanu ◽  
Victor Mihai Sacerdoțianu ◽  
Dan Nicolae Florescu ◽  
Lucian Mihai Florescu ◽  
Ion Rogoveanu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Paraneoplastic Syndrome ◽  
Renal Cell ◽  
Malignant Disease ◽  
Lung Metastases ◽  
Early Recognition ◽  
Lymphoproliferative Disorders ◽  
Cholestatic Jaundice ◽  
Disease Stage

Cholestatic jaundice is usually linked to a malignant disease when it is secondary to a mechanical obstruction of the bile duct or due to hepatic metastasis. As a paraneoplastic syndrome, cholestasis has been described in lymphoproliferative disorders, in prostate cancer and as the Stauffer syndrome with non-metastatic dysfunction in patients with renal cell carcinoma (RCC). We present the case of a 61 year old patient with a paraneoplastic manifestation with cholestatic jaundice due to RCC with kindney and lung metastases. Clinical characteristics of patients with RCC vary and sometimes manifest in a peculiar way. Cholestatic jaundice is a rare paraneoplastic syndrome associated with RCC and with the exclusion of more frequent causes, it should be taken into account in the differential diagnosis. This rare but possible association requires prompt recognition, as prognosis correlates with disease stage and influences patient’s overall survival, and an early recognition of this syndrome may improve, sometimes, patients’ outcome.

scholarly journals Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chao Liu ◽  
Jingjing Piao ◽  
Zhiyang Shang
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
General Condition ◽  
Renal Cell ◽  
Checkpoint Inhibitors ◽  
Lung Metastases ◽  
Left Lung ◽  
The Third ◽  
Bidirectional Regulation ◽  
Hyperprogressive Disease

Abstract Background Studies have shown that immune checkpoint inhibitors (ICIs) have limited efficacy and can even increase tumour burden in short time periods. This is usually called hyperprogressive disease (HPD). To date, there are few reports regarding HPD; fewer have analysed the relationship between HPD and radiotherapy combined with ICIs, and their conclusions are controversial. Case presentation A 42-year-old woman was diagnosed with stage IV renal clear cell carcinoma. The patient had previously received sorafenib and pazopanib as first- and second-line therapies, respectively. She received radiotherapy combined with nivolumab. Eighteen days after administration of the third dose of nivolumab, the patient’s general condition deteriorated; this was associated with immune-related adverse events. Computed tomography showed that the diameter of left lung metastases had sharply increased. A biopsy of the lung metastasis showed no infiltration of lymphocytes. The patient’s general condition worsened and she died of the disease on the 70th day after administration of the third dose of nivolumab. Conclusions This report describes the development of HPD following the administration of radiotherapy combined with ICIs in a case of advanced renal cell carcinoma. The case indicates that radiotherapy may show bidirectional regulation effects on anti-tumour immune response. If the immunosuppressive function of radiotherapy is dominant, combined with ICIs, it could result in HPD.

Immunotherapy for Lung Metastases of Murine Renal Cell Carcinoma

1999 ◽  
Vol 22 (4) ◽  
pp. 308-314 ◽  
Author(s):  
Nobuyasu Nishisaka ◽  
Atul Maini ◽  
Yoshihisa Kinoshita ◽  
Ryoji Yasumoto ◽  
Taketoshi Kishimoto ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Lung Metastases

scholarly journals 2586 Renal Cell Carcinoma Presenting as Paraneoplastic Syndrome Involving the Gastrointestinal Tract

2019 ◽  
Vol 114 (1) ◽  
pp. S1422-S1423
Author(s):  
Barrett Attarha ◽  
Satish Maharaj ◽  
Ciel Harris ◽  
Ron Schey ◽  
Ammar Nassri ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Gastrointestinal Tract ◽  
Cell Carcinoma ◽  
Paraneoplastic Syndrome ◽  
Renal Cell

Role of Surgery for Locally Advanced and Metastatic Renal Cell Carcinoma

2011 ◽  
Vol 9 (9) ◽  
pp. 985-993 ◽  
Author(s):  
Robert Torrey ◽  
Philippe E. Spiess ◽  
Sumanta K. Pal ◽  
David Josephson
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Metastatic Disease ◽  
Renal Cell ◽  
Locally Advanced ◽  
Disease Stage ◽  
Disease Characteristics ◽  
Multimodal Management

Both locally advanced and metastatic renal cell carcinoma (RCC) present a challenge in terms of their optimal management. This article reviews the literature and evaluates the role of surgery in the treatment of advanced RCC. Surgery is the optimal treatment for locally advanced RCC and minimal, resectable, metastatic disease. Patients with metastatic disease, and some forms of locally advanced disease, may also benefit from multimodal management with local surgical therapy and systemic treatment using either immunotherapy or targeted therapy. Regardless of the disease stage, patients with locally advanced or metastatic RCC represent heterogenous patient populations with different disease characteristics and risk factors. Individualization of care in the setting of a sound oncologic framework may optimize the risk/benefit ratio within individual patient cohorts.

Lymphocytic vasculitis a paraneoplastic syndrome associated with Renal Cell Carcinoma

2016 ◽  
Vol 4 (2) ◽  
pp. 41
Author(s):  
H Basavanagowdappa ◽  
Prathibha Pereira ◽  
KC Shashidhar ◽  
Chaithra ◽  
Ranganath ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Paraneoplastic Syndrome ◽  
Renal Cell

scholarly journals Is There an Association between Advanced Stage of Renal Cell Carcinoma and Paraneoplastic Syndrome?

2012 ◽  
Vol 21 (4) ◽  
pp. 370-374 ◽  
Author(s):  
Guan-Xiong Ding ◽  
Ning-Hong Song ◽  
Chen-Chen Feng ◽  
Guo-Wei Xia ◽  
Hao-Wen Jiang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Paraneoplastic Syndrome ◽  
Renal Cell ◽  
Advanced Stage

Does obesity affect the outcome of renal cell carcinoma?

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 444-444
Author(s):  
Mohammad Mozayen ◽  
Anteneh Tesfaye ◽  
Khalil Katato
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Community Hospital ◽  
Prognostic Significance ◽  
Disease Stage ◽  
Increased Risk ◽  
Study Population

444 Background: Obesity has been associated with increased risk of renal cell carcinoma (RCC). However the prognostic significance of obesity in the survival of patients with RCC is still undefined. Our study examined prognostic significance of obesity on the overall survival of patients (pts) with RCC in community hospital settings. Methods: A retrospective review of pts diagnosed with RCC between 1995 and 2008 in a community hospital setting was done. Pts with additional malignancies, lymphoma of the kidneys and no follow up data were excluded from the study. Demographics, body mass index(BMI) at diagnoses, pathology, disease stage, operative note, and subsequent follow up data were reviewed. The WHO BMI classification was used to group pts into Underweight (UW) < 18.5; Normal (NL): 18.5-24.99; Pre-obese (PO): 25-29.99; Obese I (Ob I): 30-34.99; Obese II (Ob II): 35-39.99; Obese III (Ob III): ≥40. The primary outcome was 3 years overall survival. Results: A total Of 205 pts reviewed, 127 (62.3%) were males, 176 (85.9%) were Caucasians. The median age of the study population was 65 (22-91). The prevalence of obesity was 42.3% in the study population; 46.2% in females and 39% in males (p=0.19). The median BMI was 28.8 (16-54.6). Pts were categorized based on their BMI as: UW (1.5%), NL (21.4%), PO (34.7%), Ob I (26%), Ob II (8.2%), and Ob III (8.2%). Clear Cell was the commonest histology (79%). Stage I was seen in 53.9%, II in 23.5%, III in 13.7% and IV in 8.8% of the study population. The 3 year overall survival for the study population was 67.3% (95% CI: 60.4-73.7). The 3-year overall survival of obese and non obese pts with RCC were 66.4% and 69.5% respectively (p=0.34). There was no difference in the 3-year overall survival of patient in the BMI groupings: (UW: 66.7%, NW: 59%, Pre-Ob: 70.6%, Obese I: 70%, II: 75%, III: 62.5%; p=0.8). Conclusions: Our study didn’t find any association between BMI and 3 year overall survival in pts with RCC. Larger randomized trials are warranted before excluding the negative impact of obesity in the overall survival of pts with renal cell carcinoma.

Sign in / Sign up

Export Citation Format

Share Document